Trends in pioglitazone use among US adults with type 2 diabetes and suspected non-alcoholic fatty liver disease.

Trends in pioglitazone use among US adults with type 2 diabetes and suspected non-alcoholic fatty liver disease. Expert Opin Investig Drugs. 2019 Dec 12;: Authors: Le P, Chaitoff A, Rothberg MB, McCullough A, Alkhouri N Abstract BackgroundWe aimed to estimate population-based trends in prevalence of coexisting type 2 diabetes (T2D) and suspected non-alcoholic fatty liver disease (NAFLD) and pioglitazone use among US adults.Research design and methodsWe conducted a cross-sectional analysis of the National Health and Nutrition Examination Survey from 2003-2016. We included people aged ≥18 years who had HbA1C>6.4%, fasting plasma glucose>125 mg/dL, or were told they had diabetes by a doctor. Suspected NAFLD was defined using hepatic steatosis index of>36. Prevalence was estimated for each 2-year survey cycle. Trends were analyzed using logistic regression, accounting for the complex survey design.ResultsTotal sample size was 40,323 US adults, of which 5,690 had T2D. Age-adjusted prevalence of T2D with NAFLD increased from 5.6% in 2003-2004 to 6.8% in 2015-2016 (p-value
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research

Related Links:

This article reviews the most updated information about NAFLD-related HCC and provides some insight into strategies that must be considered to reduce its potential disease burden.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
Ali Mahzari1, Songpei Li1, Xiu Zhou1,2, Dongli Li2, Sherouk Fouda1, Majid Alhomrani1, Wala Alzahrani1, Stephen R. Robinson1 and Ji-Ming Ye1,2* 1Lipid Biology and Metabolic Disease Laboratory, School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia 2School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China The present study investigated the effects of matrine on non-alcoholic steatohepatitis (NASH) in mice induced by a methionine choline-deficient (MCD) diet and the mechanism involved. The study was performed in C57B/6J mice fed a MCD diet for 6 weeks to induce NAS...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 12 November 2018Source: Journal of Clinical and Experimental HepatologyAuthor(s): Onkar Bedi, Savera Aggarwal, Nirupma Trehanpati, Gayatri Ramakrishna, Pawan KrishanAbstractDiabetes mellitus is a rising epidemic in most part of the world and is often associated with multiple organ disorders such as kidney, liver and cardiovascular diseases. Liver is a major metabolic hub and the metabolic disorders associated with diabetes result in liver dysfunctions culminating in spectrum of liver diseases such as fatty liver disorders, cirrhosis and hepatocellular carcinoma. The intervention strategie...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterized as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death; it is associated with extrahepatic manifestations such as chronic kidney disease cardiovascular disease and sleep apnea.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Public Health Source Type: research
As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterised as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death. NAFLD is also associated with extrahepatic manifestations such as chronic kidney disease, cardiovascular disease and sleep apnoea.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Public Health Source Type: research
Abstract Hepatocellular carcinoma is the third most frequent cause of cancer death worldwide, particularly in Asia and Africa. Most cases complicate an underlying liver cirrhosis due to hepatitis B or C chronic virus infection or alcoholic abuse. But, following the current epidemics of obesity and type 2 diabetes, it appears that these diseases, associated in metabolic syndrome, are responsible for non alcoholic fatty liver disease at risk of HCC frequently before the stage of cirrhosis. Recent hypotheses consider that in the near future, cancer deaths due to HCC will overpass in USA those due to breast or colorec...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
Because of global epidemics of obesity and type 2 diabetes, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing both in Europe and USA becoming one of the most frequent causes of chronic liver disease and predictably, one of the leading causes of liver transplantation (LT) both for end-stage liver disease and hepatocellular carcinoma. For most transplant teams around the world this will raise many challenges in terms on pre- and post-transplant management. Here we review the multifaceted impact of NAFLD on liver transplantation and will discuss: (1) NAFLD as frequent cause of cryptogenic cirrhosis, en...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Review Source Type: research
Abstract Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and its prevalence is increasing in relation to the epidemics of obesity and type 2 diabetes mellitus, via non-alcoholic fatty liver disease (NAFLD). Unhealthy lifestyles associated with metabolic disorders are per se risk conditions for NAFLD progression, and specific gene polymorphisms may also favor oncogenesis, particularly in the presence of advanced fibrosis or cryptogenic cirrhosis. However, NAFLD-associated HCC may also develop in non-cirrhotic NAFLD and is frequently diagnosed at a more advanced tumor stage, compared with...
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research
I tell my patients to avoid drinking soda not just because they make you fat. Each sip of soda affects your health. Soda puts you at risk for health problems like metabolic syndrome. This is a collection of symptoms that can lead to diabetes, heart disease and other chronic diseases, like cancer. Soft drinks are the beverage of choice for millions of Americans. The latest research now reveals that sodas are a major cause of visceral fat — the deadliest kind of fat you can have, inflaming your tissues, rotting your blood vessels and upsetting your body chemistry. In a minute I’m going to tell you about a great ...
Source: Al Sears, MD Natural Remedies - Category: Complementary Medicine Authors: Tags: Heart Health heart disease metabolic syndrome Visceral Fat Source Type: news
Conclusions: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous. (Hepatology 2015)
Source: Hepatology - Category: Internal Medicine Authors: Tags: Steatohepatitis and Metabolic Liver Disease Source Type: research
More News: Actos | Alcoholism | Cirrhosis | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Epidemics | Epidemiology | Fatty Liver Disease (FLD) | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Study | Urology & Nephrology